Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, M. L.
Right arrow Articles by Weber, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, M. L.
Right arrow Articles by Weber, R. F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 4 632-636, Copyright © 1997 by American Diabetes Association

ARTICLES

Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM

ML Jacobs, FH Derkx, T Stijnen, SW Lamberts and RF Weber
Department of Internal Medicine III, University Hospital Dijkzigt, Rotterdam, The Netherlands.

OBJECTIVE: To investigate whether long-acting somatostatin (SMS) can suppress renal hyperfiltration in patients with IDDM. RESEARCH DESIGN AND METHODS: A double-blind, randomized treatment of nine patients with IDDM was used. Selection criteria were renal hyperfiltration (glomerular filtration rate [GFR] > or = 129 ml.min-1.1.73 m2) and absence of hypertension and macroalbuminuria. Treatment was either with a long-acting SMS analog (Somatulin, 30 mg) or with placebo, given by intramuscular injections every 10 days for 9 months. GFR, effective renal plasma flow (ERPF), IGF-I, and 24-h growth hormone (GH) profiles were used as evaluation parameters. RESULTS: Five patients were randomized to Somatulin, four patients to placebo. One of the patients treated with Somatulin stopped after 3 months because of persistent abdominal discomfort after the injections. Somatulin treatment for 3 months lowered GFR and ERPF compared with placebo (P < 0.05). After 9 months, the differences were no longer significant. After 3 months, IGF-I concentrations were decreased in all Somatulin-treated patients. GH secretion tended to increase in the placebo group. CONCLUSIONS: The administration of long-acting Somatulin to patients with IDDM and renal hyperfiltration leads to only a temporary reduction of ERPF/GFR.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Muller, J. J. Kopchick, A. Flyvbjerg, and A. J. van der Lely
Growth Hormone Receptor Antagonists
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1503 - 1511.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
K. R. Tuttle, M. E. Puhlman, S. K. Cooney, and R. A. Short
Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes
Am J Physiol Renal Physiol, January 1, 2002; 282(1): F103 - F112.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
D. A. Balster, M. S. O'Dorisio, M. A. Summers, and M. A. Turman
Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney
Am J Physiol Renal Physiol, March 1, 2001; 280(3): F457 - F465.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Giustina and J. D. Veldhuis
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human
Endocr. Rev., December 1, 1998; 19(6): 717 - 797.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.